EUVIMEDEUVIMED entdecken
Open Access

Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics

Bruna Fernandes, Colleen P Olkowski, Behnaz Ghaemi, Falguni Basuli, Jianfeng Shi, Dale O Kiesewetter, Lixin Lang, Edmondson Elijah, Rolf Swenson, Peter L Choyke, Frank I Lin, Orit Jacobson

Journal of Controlled Release · 2025

DOI: 10.1016/j.jconrel.2025.01.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025. Verfasst von Bruna Fernandes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: B7 Antigens, Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS, U.S. Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B7-H3, an immunomodulatory protein overexpressed in many cancers, is associated with tumor aggressiveness and poor prognosis, making it a crucial target for imaging to elucidate its role in cancer progression and guide therapeutic interventions. This study employed PET imaging to investigate the in vivo delivery and pharmacokinetics of two anti-B7-H3 antibodies, Ab-1 and Ab-2, in mouse xenograft models with varying B7-H3 expression levels. The antibodies were radiolabeled with [89Zr]Zr and evaluated through PET imaging, biodistribution studies, and in vitro assays to assess binding, tumor uptake, and retention. [89Zr]Zr-Ab-1 demonstrated high initial tumor uptake in B7-H3 positive xenografts but exhibited unexpected decreasing retention over time. This clearance was likely attributed to proteolytic cleavage mediated by matrix metalloproteinases in the tumor and the tumor microenvironment. Conversely, [89Zr]Zr-Ab-2 showed more stable tumor retention but lower overall uptake. Further investigation revealed that Ab-1 had affinity for both 4Ig and 2Ig B7-H3 isoforms, while Ab-2 bound exclusively to the 4Ig isoform. This differential binding to B7-H3 isoforms may explain the observed variations in tumor uptake and retention between the two antibodies. The study provides insights into the complex dynamics of B7-H3 targeted antibodies in vivo, highlighting how antibody characteristics, including isoform-specific binding, and tumor factors influence their behavior. These findings have potential implications for optimizing radiotherapy strategies, suggesting the possibility of tailored approaches based on antibody properties and tumor biology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7 AntigensNeoplasmsAntibodies, MonoclonalAnimalsPositron-Emission TomographyHumansZirconiumTissue DistributionRadioisotopesCell Line, TumorMiceFemaleMice, Nude

Stichwörter der Autor:innen

Antibody pharmacokineticsB7-H3Matrix metalloproteinasesPET imagingZirconium-89 labeling

Substanzen

B7 AntigensZirconiumRadioisotopesZirconium-89CD276 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, MD 20850, USA.
  • Molecular Tracer and Imaging Core Facility, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, USA.
  • Molecular Histopathology Lab, Frederick National Laboratory for Cancer Research, NCI, Frederick, MD 21701, USA.
  • Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: orit.jacobsonweiss@nih.gov.

Förderung

  • NCI NIH HHS
  • Intramural NIH HHS
  • U.S. Department of Health and Human Services
  • National Institutes of Health
  • Foundation for the National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Fernandes, B., Olkowski, C. P., Ghaemi, B., Basuli, F., Shi, J., Kiesewetter, D. O., Lang, L., Elijah, E., Swenson, R., Choyke, P. L., Lin, F. I., & Jacobson, O. (2025). Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.01.030

Vancouver

Fernandes B, Olkowski CP, Ghaemi B, Basuli F, Shi J, Kiesewetter DO, et al. Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.01.030

BibTeX
@article{Fernandes2025,
  author = {Fernandes, Bruna and Olkowski, Colleen P and Ghaemi, Behnaz and Basuli, Falguni and Shi, Jianfeng and Kiesewetter, Dale O and Lang, Lixin and Elijah, Edmondson and Swenson, Rolf and Choyke, Peter L and Lin, Frank I and Jacobson, Orit},
  title = {Unraveling the dynamics of B7-H3-targeting therapeutic antibodies in cancer through PET imaging and antibody pharmacokinetics},
  journal = {Journal of Controlled Release},
  year = {2025},
  doi = {10.1016/j.jconrel.2025.01.030}
}
Kostenlos starten →